FDA approves Tregzi as first Treg cell therapy for allogenic transplant in blood cancers

The FDA has approved an allogeneic regulatory T cell immunotherapy for use in matched-donor hematopoietic stem cell transplantation in patients with blood cancers, to improve survival for chronic graft-versus-host disease.According to the manufacturer, this newly approved therapy (Tregzi, Orca Bio) is a “personalized treatment manufactured for each individual patient using living cells from